Profitability:
Adjusted EBITDA of $70.4M in 2025 with a 29% margin and Q4 2025 margin at 29% indicate disciplined cost control despite softer revenue. Management’s 2026 guide still anticipates mid‑20s margins, underscoring ongoing profit focus.
Healthy Cash Flow:
Cash flow from operations totaled $53.8M in 2025 with positive unlevered free cash flow. This cash generation provides flexibility while the company works to stabilize growth.
Future-Ready Strategy:
Management emphasizes improving retention, upsell/cross‑sell, and product integration, alongside continued product innovation and ecosystem alignment. Recognition such as Databricks’ 2024 Healthcare & Life Sciences Partner of the Year signals integration momentum in modern data stacks.
